The same mRNA technology behind COVID-19 vaccines is now being used in the fight against cancer, and the University of ...

Adding pamrevlumab to standard chemotherapy did not improve survival in patients with locally advanced pancreatic cancer ...

The addition of high-dose IV vitamin C to standard chemotherapy nearly doubled OS for patients with advanced pancreatic cancer, according to results of a randomized phase 2 trial.Vitamin C also ...

With such volatility, SLXN has emerged as one of the most talked-about stocks of the day, creating a buzz in the biotechnology sector. Let’s dive into the details behind this remarkable movement and ...

Recent trends reveal a sharp rise in cancer cases in India, with younger patients and a lack of effective screening programs ...

Some oncologists suggest that, for certain early cancers not at risk of spreading, the term “cancer” should be avoided.

The clearance is a step forward in AstraZeneca and Daiichi Sankyo’s plan to position antibody-drug conjugates like Enhertu ...

CAYMAN ISLANDS - Silexion Therapeutics Corp. (NASDAQ: SLXN), a biotech firm focusing on RNA interference (RNAi) treatments, ...

A team led by UT Southwestern scientists has discovered a mechanism that promotes metastasis in pancreatic, breast, and ...

A Peter Mac-led international clinical trial has shown adding an immunotherapy drug to the chemotherapy that patients receive ...

Silexion Therapeutics (SLXN) announced new preclinical data for SIL-204, its next-generation siRNA therapeutic candidate. The findings ...

New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating ...